Currently Enrolling:
A phase II study of binimetinib in combination with imatinib in patients with advanced KIT-mutant melanoma
NCT04598009
PIs: Katy Tsai, MD; Iwei Yeh, MD, PhD
Sponsor: Pfizer
Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) Combination in Metastatic Melanoma Refractory to Prior Immune Checkpoint Inhibitor Therapy with and without CNS Disease
NCT05695898
PIs: Adil Daud, MD; Saya Jacob, MD
Sponsor: Xencor
A Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
NCT06281678
PI: Katy Tsai, MD
Sponsor: Innovent
Study Contact: Rajabi, Marjan <[email protected]>
A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
NCT06264180
PI: Katy Tsai, MD
Sponsor: ReplimuneStudy Contact: Sleeper, Olivia <[email protected]>
A PHASE 2 AND PHASE 3 PERI-OPERATIVE TRIAL OF FIANLIMAB AND CEMIPLIMAB COMPARED WITH ANTI-PD1 ALONE IN PATIENTS WITH
RESECTABLE STAGE III AND IV MELANOMA
NCT06190951
PI: Adil Daud, MD
Sponsor: Regeneron
Study Contact: Micu, Markee <[email protected]>
A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN’S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]
NCT06346067
PI: Adil Daud, MD
Sponsor: Erasca
Study Contact: Phen, Dary <[email protected]>
A PHASE 3 TRIAL OF FIANLIMAB (ANTI-LAG-3) AND CEMIPLIMAB VERSUS PEMBROLIZUMAB IN THE ADJUVANT SETTING IN PATIENTS WITH COMPLETELY RESECTED HIGH-RISK MELANOMA
NCT05608291
PI: Adil Daud, MD
Sponsor: Regeneron
Study Contact: Nimene, Anna-Marie <[email protected]>
IDE196 (DAROVASERTIB) IN COMBINATION WITH CRIZOTINIB VERSUS INVESTIGATOR’S CHOICE OF TREATMENT AS FIRST-LINE THERAPY IN HLA-A2 NEGATIVE METASTATIC UVEAL MELANOMA (DAR-UM-2)
NCT05987332
PI: Katy Tsai, MD
Sponsor: Ideaya
Study Contact: Phen, Dary <[email protected]>
Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT03589339
PI: Jason Chan, MD
Sponsor: Nanobiotix
Study Contact: Sleeper, Olivia <[email protected]>
A phase II study of binimetinib in combination with imatinib in patients with advanced KIT-mutant melanoma
NCT04598009
PI: Katy Tsai, MD
Sponsor: Pfizer/ Investigator Initiated Study
Study Contact: Rajabi, Marjan <[email protected]>
An Open-Label, Multicenter, Phase 1B Study of RP1 in Organ Transplant Recipients with Advanced Cutaneous Squamous Cell Carcinoma
NCT04349436
PI: Katy Tsai, MD
Sponsor: Replimune
Study Contact: Nimene, Anna-Marie <[email protected]>
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA
NCT06246916
PI: Katy Tsai, MD
Sponsor: Regeneron
Study Contact: Nimene, Anna-Marie <[email protected]>